The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 13, 2018
Filed:
May. 12, 2017
Applicant:
Theravance Biopharma R&d Ip, Llc, South San Francisco, CA (US);
Inventors:
Adam D. Hughes, Belmont, CA (US);
Erik Fenster, San Bruno, CA (US);
Melissa Fleury, Brisbane, CA (US);
Roland Gendron, San Francisco, CA (US);
Edmund J. Moran, San Francisco, CA (US);
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/00 (2006.01); A61K 31/21 (2006.01); A61K 31/197 (2006.01); C07C 271/22 (2006.01); C07D 317/40 (2006.01); C07C 231/02 (2006.01); C07C 233/56 (2006.01); C07C 243/30 (2006.01); C07D 319/06 (2006.01); C07D 207/263 (2006.01); A61K 31/24 (2006.01); A61K 31/27 (2006.01); A61K 31/365 (2006.01); A61K 45/06 (2006.01); C07C 243/28 (2006.01); C07C 243/26 (2006.01); A61K 31/167 (2006.01); A61K 31/165 (2006.01); A61K 31/16 (2006.01); A61K 31/166 (2006.01); A61K 31/164 (2006.01);
U.S. Cl.
CPC ...
A61K 31/197 (2013.01); A61K 31/24 (2013.01); A61K 31/27 (2013.01); A61K 31/365 (2013.01); A61K 45/06 (2013.01); C07C 231/02 (2013.01); C07C 233/56 (2013.01); C07C 243/26 (2013.01); C07C 243/28 (2013.01); C07C 243/30 (2013.01); C07C 271/22 (2013.01); C07D 207/263 (2013.01); C07D 317/40 (2013.01); C07D 319/06 (2013.01); A61K 31/16 (2013.01); A61K 31/164 (2013.01); A61K 31/165 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01);
Abstract
In one aspect, the invention relates to compounds having the formula: where R-R, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.